Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Cyclophosphamide, Etoposide, and Cisplatin in Relapsed NHL
NCT00002488Phase 2Unknown
- Sponsor
- The Ottawa Hospital Cancer Centre
- Start
- Dec 1991
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, cyclophosphamide and etoposide in non-Hodgkin lymphoma (NHL), sponsored by The Ottawa Hospital Cancer Centre. Primary endpoints: Complete Response Rate and Toxicity of Intensification Chemotherapy. Status: unknown.
02
Drugs
cisplatincyclophosphamideetoposide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00002488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002488.